Toward a cure for chronic myeloid leukemia

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 7971-7974

  O'Hare, Thomas ^a,b   Deininger, Michael W ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AP 24534; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; BOSUTINIB; CRK LIKE PROTEIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; DCC 2036; IMATINIB; NILOTINIB; PHA 739358; SGX 393; UNCLASSIFIED DRUG; XL 228; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG BINDING; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ARTICLE; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; MUTATION;

DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 58149342071     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1486     Document Type: Review

References (35)

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
2. Savona M, Talpaz M. Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 2008;8:341 -50.
3. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008. [Epub ahead of print].
4. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon a plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
5. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876 -80.
6. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938-42.
7. Weisberg E, Manley PW, Breitenstein W, et al. Characterization ofAMN107, a selective inhibitor of wild-type and mutant Bcr-Abl. Cancer Cell 2005;7:129 -41.
8. Kantarjian H, Giles F,Wunderle L, et al. Nilotinib in ima-tinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542 -51.
9. Shah NP,Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL ki-nase inhibitor. Science 2004;305:399 -401.
10. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531 -41.
11. O'HareT, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65: 4500-5.
12. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005;102:3395-400.
13. Vajpai N, Strauss A, Fendrich G, et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 2008;283:18292-302.
14. Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008; 112:516-8.
15. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109: 3207-13.
16. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic my-elogenous leukemia. Blood 2008;111:1834-9.
17. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110: 2242-9.
18. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007;117:2562 -9.
19. Wu J, Meng F, Lu H, et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 2008;111:3821 -9.
20. Van Etten RA, Chan WW, Zaleskas VM, et al. DCC-2036: a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model. Blood 2007;110:142a.
21. Giles FJ, CortesJ, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with theT315IBCR-ABL mutation. Blood 2007;109:500-2.
22. Paquette RL, Shah N, Sawyers CL, et al. PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315Imutations of BCR-ABL. Blood 2007; 110:312a.
23. Shah N, Kasap C, Paquette R, et al. Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228. Blood 2007; 110:146a.
24. O'Hare T, Eide CA,Tyner JW, et al. SGX393 inhibits the CML mutant Bcr-AblT315Iand preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci U S A 2008;105:5507 -12.
25. Rivera VM, Xu Q, Wang F, et al. Potent antitumor activity of AP24534, an orally active inhibitor of Bcr-Abl variants including T315I, in in vitro and in vivo models of chronic myeloid leukemia (CML). Blood 2007;110:312a.
26. Cortes J, O'Brien SG, Jabbour E, et al. Efficacy of nilotinib (AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood 2007; 110:17a.
27. Cortes J, O'Brien SG, Jones D, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood 2007;110:17a.
28. Forrest DL,Trainor S, Brinkman RR, et al. Cytoge-netic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 2008 [Epub ahead of print].
29. Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008 [Epub ahead ofprint].
30. Krause DS,Van Etten RA. Bedside to bench: interfering with leukemic stem cells. Nat Med 2008;14: 494-5.
31. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60.
32. Burchert A, Wolfl S, Schmidt M, et al. Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T- cell response in chronic myeloid leukemia. Blood 2003;101:259 -64.
33. Kantarjian H, Cortes J, Le Coutre P, et al. A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors. Blood 2007;110:144a.
34. Cortes J, Kantarjian H, Baccarani M, et al. A phase 1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib. Blood 2006;108:54a.
35. Kantarjian H,Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873 -8.